VRAX vs. SHPH, TCBP, JAGX, TCRT, SRNE, GOVX, BFRI, IMCC, BNOX, and LIXT
Should you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Shuttle Pharmaceuticals (SHPH), TC Biopharm (TCBP), Jaguar Health (JAGX), Alaunos Therapeutics (TCRT), Sorrento Therapeutics (SRNE), GeoVax Labs (GOVX), Biofrontera (BFRI), IM Cannabis (IMCC), Bionomics (BNOX), and Lixte Biotechnology (LIXT). These companies are all part of the "pharmaceutical products" industry.
Virax Biolabs Group (NASDAQ:VRAX) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, community ranking, analyst recommendations, dividends, institutional ownership and media sentiment.
Virax Biolabs Group's return on equity of 0.00% beat Shuttle Pharmaceuticals' return on equity.
In the previous week, Virax Biolabs Group had 2 more articles in the media than Shuttle Pharmaceuticals. MarketBeat recorded 4 mentions for Virax Biolabs Group and 2 mentions for Shuttle Pharmaceuticals. Virax Biolabs Group's average media sentiment score of 0.96 beat Shuttle Pharmaceuticals' score of 0.30 indicating that Virax Biolabs Group is being referred to more favorably in the media.
8.6% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by insiders. Comparatively, 39.6% of Shuttle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Virax Biolabs Group and Shuttle Pharmaceuticals both received 0 outperform votes by MarketBeat users.
Virax Biolabs Group has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Shuttle Pharmaceuticals has a beta of -0.91, indicating that its stock price is 191% less volatile than the S&P 500.
Virax Biolabs Group has higher revenue and earnings than Shuttle Pharmaceuticals.
Summary
Virax Biolabs Group beats Shuttle Pharmaceuticals on 9 of the 9 factors compared between the two stocks.
Get Virax Biolabs Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Virax Biolabs Group Competitors List
Related Companies and Tools
